 NantKwest, Inc. Nasdaq: NK, a clinical-stage, natural killer cell-based therapeutics company, announced today the closing of its previously announced underwritten public offering of an aggregate of 8,521,500 shares of its common stock 4,811,500 shares at a price to the public of 9.50 per share and 3,710,000 shares at a price of 12.12 per share to NantKwests chairman, chief executive officer and principal stockholder, Dr. Patrick Soon-Shiong, which includes 1,111,500 shares sold upon full exercise of the underwriters option to purchase additional shares at a public offering price of 9.50 per share, less the underwriting discounts and commissions. All of the shares were offered by NantKwest. Including the option exercise, the aggregate gross proceeds of the offering were approximately 90.7 million, before deducting the underwriting discounts and commissions and other offering expenses. 